{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462248630
| IUPAC_name = (''RS'')-3-(3-ethyl-1-methylazepan-3-yl)phenol
| image = Meptazinol_racemate2DCSD.svg
| width = 300
| image2 =  
| width2 =  
| chirality = [[Racemic mixture]]
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|meptazinol}}
| licence_EU = <!-- EMEA requires brand name -->
| licence_US = <!-- FDA may use generic name -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = Schedule 4
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = <!-- OTC / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| dependency_liability = Low
| routes_of_administration = Oral, [[intramuscular|IM]], [[intravenous|IV]]

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism = The peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours.
| elimination_half-life = Half-Life (1.4–4 hours).
| excretion = The drug is rapidly metabolised to the glucuronide, and mostly excreted in the urine.

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 59263-76-2
| ATC_prefix = N02
| ATC_suffix = AX05
| ATC_supplemental =  
| PubChem = 41049
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 37469
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 18Y7S5JKZD
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08182
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 314437

<!--Chemical data-->
| chemical_formula =  
| C=15 | H=23 | N=1 | O=1 
| molecular_weight = 233.34922 g/mol
| smiles = OC1=CC=CC(C2(CCCCN(C2)C)CC)=C1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H23NO/c1-3-15(9-4-5-10-16(2)12-15)13-7-6-8-14(17)11-13/h6-8,11,17H,3-5,9-10,12H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JLICHNCFTLFZJN-UHFFFAOYSA-N
| synonyms =  
| density =  
| melting_notes =  
| boiling_point =  
| solubility =  
| specific_rotation =  
| sec_combustion =  
}}

'''Meptazinol''' (trade name '''Meptid''') is an [[opioid]] [[analgesic]] developed by Wyeth in the 1970s.<ref>{{ cite patent | country = US | status = patent | number = 4197239 | title = Hexahydroazepine, Piperidine and Pyrrolidine Derivatives | gdate = 1980-04-08 | inventor = Cavalla JF, Shepherd RG, White AC | assign1 = Wyeth }}</ref> Indications for use in moderate to severe [[pain]], most commonly used to treat pain in [[obstetrics]] ([[childbirth]]).

Meptazinol is a 3-phenylazepane derivative, whereas the other phenazepanes like [[ethoheptazine]] and [[proheptazine]] are [[4-phenylazepane]]s.

A partial [[mu opioid receptor|µ-opioid receptor]] [[agonist]], its mixed [[agonist]]/[[Receptor antagonist|antagonist]] activity affords it a lower risk of [[physical dependence|dependence]] and [[drug abuse|abuse]] than full µ [[agonist]]s like [[morphine]]. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other [[opioid]]s such as [[morphine]], [[pentazocine]], or [[buprenorphine]].<ref name="Holmes 1985">{{ cite journal |vauthors=Holmes B, Ward A | title = Meptazinol. A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy | journal = Drugs | year = 1985 | volume = 30 | issue = 4 | pages = 285–312 | pmid = 2998723 | doi=10.2165/00003495-198530040-00001}}</ref>

==References==
{{Reflist|30em}}

==External links==
* {{MeshName|Meptazinol}}

{{Analgesics}}
{{Opioidergics}}

[[Category:Synthetic opioids]]
[[Category:Azepanes]]
[[Category:Phenols]]


{{analgesic-stub}}